Prenatal MAM Exposure Raises Kynurenic Acid Levels in the Prefrontal Cortex of Adult Rats

Overview

Journal Pharmacol Rep

Specialty Pharmacology

Date 2024 May 24

PMID 38789891

Authors

Francesca Frescura

Tibor Stark

Edoardo Tiziani

Serena Di Martino

Jana Ruda-Kucerova

Filippo Drago

Luca Ferraro

Vincenzo Micale

Sarah Beggiato

Affiliations

Soon will be listed here.

Abstract

Background: Elevated brain levels of kynurenic acid (KYNA), a metabolite in the kynurenine pathway, are associated with cognitive dysfunctions, which are nowadays often considered as fundamental characteristics of several psychopathologies; however, the role of KYNA in mental illnesses, such as schizophrenia, is not fully elucidated. This study aimed to assess KYNA levels in the prefrontal cortex (PFC) of rats prenatally treated with methylazoxymethanol (MAM) acetate, i.e., a well-validated neurodevelopmental animal model of schizophrenia. The effects of an early pharmacological modulation of the endogenous cannabinoid system were also evaluated.

Methods: Pregnant Sprague-Dawley rats were treated with MAM (22 mg/kg, ip) or its vehicle at gestational day 17. Male offspring were treated with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day, ip) or with the typical antipsychotic haloperidol (0.6 mg/kg/day, ip) from postnatal day (PND) 19 to PND39. The locomotor activity and cognitive performance were assessed in the novel object recognition test and the open field test in adulthood. KYNA levels in the PFC of prenatally MAM-treated rats were also assessed.

Results: A significant cognitive impairment was observed in prenatally MAM-treated rats (p < 0.01), which was associated with enhanced PFC KYNA levels (p < 0.05). The peripubertal AM251, but not haloperidol, treatment ameliorated the cognitive deficit (p < 0.05), by normalizing the PFC KYNA content in MAM rats.

Conclusions: The present findings suggest that the cognitive deficit observed in MAM rats may be related to enhanced PFC KYNA levels which could be, in turn, mediated by the activation of cannabinoid CB1 receptor. These results further support the modulation of brain KYNA levels as a potential therapeutic strategy to ameliorate the cognitive dysfunctions in schizophrenia.

References

Ferraro L, Tomasini M, Beggiato S, Gaetani S, Cassano T, Cuomo V . Short- and long-term consequences of prenatal exposure to the cannabinoid agonist WIN55,212-2 on rat glutamate transmission and cognitive functions. J Neural Transm (Vienna). 2009; 116(8):1017-27. DOI: 10.1007/s00702-009-0230-0. View

Higuera-Matas A, Ucha M, Ambrosio E . Long-term consequences of perinatal and adolescent cannabinoid exposure on neural and psychological processes. Neurosci Biobehav Rev. 2015; 55:119-46. DOI: 10.1016/j.neubiorev.2015.04.020. View

Drazanova E, Ruda-Kucerova J, Kratka L, Stark T, Kuchar M, Maryska M . Different effects of prenatal MAM vs. perinatal THC exposure on regional cerebral blood perfusion detected by Arterial Spin Labelling MRI in rats. Sci Rep. 2019; 9(1):6062. PMC: 6465353. DOI: 10.1038/s41598-019-42532-z. View

Hurd Y, Manzoni O, Pletnikov M, Lee F, Bhattacharyya S, Melis M . Cannabis and the Developing Brain: Insights into Its Long-Lasting Effects. J Neurosci. 2019; 39(42):8250-8258. PMC: 6794936. DOI: 10.1523/JNEUROSCI.1165-19.2019. View

Bara A, Ferland J, Rompala G, Szutorisz H, Hurd Y . Cannabis and synaptic reprogramming of the developing brain. Nat Rev Neurosci. 2021; 22(7):423-438. PMC: 8445589. DOI: 10.1038/s41583-021-00465-5. View

Nashed M, Hardy D, Laviolette S . Prenatal Cannabinoid Exposure: Emerging Evidence of Physiological and Neuropsychiatric Abnormalities. Front Psychiatry. 2021; 11:624275. PMC: 7841012. DOI: 10.3389/fpsyt.2020.624275. View

Di Bartolomeo M, Stark T, Di Martino S, Iannotti F, Ruda-Kucerova J, Romano G . The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology. Int J Mol Sci. 2023; 24(4). PMC: 9962163. DOI: 10.3390/ijms24043907. View

Lin A, Dent G, Davies S, Dominguez Z, Cioffredi L, McLemore G . Prenatal cannabinoid exposure: why expecting individuals should take a pregnancy pause from using cannabinoid products. Front Pediatr. 2023; 11:1278227. PMC: 10598870. DOI: 10.3389/fped.2023.1278227. View

Beggiato S, Ieraci A, Tomasini M, Schwarcz R, Ferraro L . Prenatal THC exposure raises kynurenic acid levels in the prefrontal cortex of adult rats. Prog Neuropsychopharmacol Biol Psychiatry. 2020; 100:109883. PMC: 7260707. DOI: 10.1016/j.pnpbp.2020.109883. View

10.

Beggiato S, Ieraci A, Zuccarini M, Di Iorio P, Schwarcz R, Ferraro L . Alterations in rat prefrontal cortex kynurenic acid levels are involved in the enduring cognitive dysfunctions induced by tetrahydrocannabinol exposure during the adolescence. Front Psychiatry. 2022; 13:996406. PMC: 9722723. DOI: 10.3389/fpsyt.2022.996406. View

11.

Mereu G, Fa M, Ferraro L, Cagiano R, Antonelli T, Tattoli M . Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci U S A. 2003; 100(8):4915-20. PMC: 153655. DOI: 10.1073/pnas.0537849100. View

12.

Beggiato S, Borelli A, Tomasini M, Morgano L, Antonelli T, Tanganelli S . Long-lasting alterations of hippocampal GABAergic neurotransmission in adult rats following perinatal Δ-THC exposure. Neurobiol Learn Mem. 2017; 139:135-143. DOI: 10.1016/j.nlm.2016.12.023. View

13.

Pinky P, Bloemer J, Smith W, Moore T, Hong H, Suppiramaniam V . Prenatal cannabinoid exposure and altered neurotransmission. Neuropharmacology. 2019; 149:181-194. DOI: 10.1016/j.neuropharm.2019.02.018. View

14.

Stark T, Di Martino S, Drago F, Wotjak C, Micale V . Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacol Res. 2021; 174:105938. DOI: 10.1016/j.phrs.2021.105938. View

15.

Schwarcz R, Bruno J, Muchowski P, Wu H . Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13(7):465-77. PMC: 3681811. DOI: 10.1038/nrn3257. View

16.

Schwarcz R, Stone T . The kynurenine pathway and the brain: Challenges, controversies and promises. Neuropharmacology. 2016; 112(Pt B):237-247. PMC: 5803785. DOI: 10.1016/j.neuropharm.2016.08.003. View

17.

Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom L, Engberg G . Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001; 313(1-2):96-8. DOI: 10.1016/s0304-3940(01)02242-x. View

18.

Schwarcz R, Rassoulpour A, Wu H, Medoff D, Tamminga C, Roberts R . Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001; 50(7):521-30. DOI: 10.1016/s0006-3223(01)01078-2. View

19.

Sathyasaikumar K, Stachowski E, Wonodi I, Roberts R, Rassoulpour A, McMahon R . Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2010; 37(6):1147-56. PMC: 3196941. DOI: 10.1093/schbul/sbq112. View

20.

Linderholm K, Skogh E, Olsson S, Dahl M, Holtze M, Engberg G . Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2010; 38(3):426-32. PMC: 3329991. DOI: 10.1093/schbul/sbq086. View